donepezil hydrochloride; memantine hydrochloride - Profile

What are the generic drug sources for donepezil hydrochloride; memantine hydrochloride and what is the scope of patent protection?

Donepezil hydrochloride; memantine hydrochloride is the generic ingredient in two branded drugs marketed by Amneal, Ani Pharms, Macleods Pharms Ltd, Xiamen Lp Pharm Co, and Abbvie, and is included in five NDAs. There are two patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Donepezil hydrochloride; memantine hydrochloride has sixty-seven patent family members in nineteen countries.

There is one tentative approval for this compound.

Summary for donepezil hydrochloride; memantine hydrochloride

International Patents:	67
US Patents:	2
Tradenames:	2
Applicants:	5
NDAs:	5
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for donepezil hydrochloride; memantine hydrochloride

Generic filers with tentative approvals for DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		10MG;21MG	CAPSULE, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NAMZARIC	Capsules	donepezil hydrochloride; memantine hydrochloride	7 mg/10 mg	206439	1	2016-09-26
NAMZARIC	Capsules	donepezil hydrochloride; memantine hydrochloride	21 mg/10 mg	206439	1	2016-09-23
NAMZARIC	Capsules	donepezil hydrochloride; memantine hydrochloride	14 mg/10 mg and 28 mg/10 mg	206439	1	2015-05-18

US Patents and Regulatory Information for donepezil hydrochloride; memantine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	208328-003	Feb 27, 2025	AB	RX	No	No
Amneal	MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	208328-001	Jan 27, 2017	AB	RX	No	No
Amneal	MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	208328-004	Feb 27, 2025	AB	RX	No	No
Amneal	MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	208328-002	Jan 27, 2017	AB	RX	No	No
Ani Pharms	MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	208237-001	Dec 15, 2023	AB	RX	No	No
Macleods Pharms Ltd	MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	208672-001	Jul 15, 2025	AB	RX	No	No
Macleods Pharms Ltd	MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	208672-002	Jul 15, 2025	AB	RX	No	No

Expired US Patents for donepezil hydrochloride; memantine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-002	Dec 23, 2014	8,293,794
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-003	Jul 18, 2016	8,293,794
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-004	Jul 18, 2016	8,338,485
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-004	Jul 18, 2016	8,293,794
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-004	Jul 18, 2016	8,580,858
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-004	Jul 18, 2016	8,338,486
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-002	Dec 23, 2014	8,338,485

EU/EMA Drug Approvals for donepezil hydrochloride; memantine hydrochloride

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
H. Lundbeck A/S	Acrescent	memantine hydrochloride, donepezil hydrochloride	EMEA/H/C/002424Treatment of Alzheimers disease	Refused	no	no	no		2013-02-20
Merz Pharmaceuticals GmbH	Balaxur	memantine hydrochloride, donepezil hydrochloride	EMEA/H/C/002708	Refused	no	no	no		2013-02-20

International Patents for donepezil hydrochloride; memantine hydrochloride

Country	Patent Number	Title	Estimated Expiration
Japan	2009173669	COMPOSITION CONTAINING SUSTAINED RELEASE COATING OR MATRIX AND NMDA RECEPTOR ANTAGONIST, AND METHOD FOR ADMINISTRATION OF SUCH NMDA ANTAGONIST TO SUBJECT
Australia	2005309601	Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject
Japan	2008520736
Austria	E481096
China	101686945	Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
World Intellectual Property Organization (WIPO)	2006121560
Mexico	2007012374	METODOS Y COMPOSICIONES PARA EL TRATAMIENTO DE CONDICIONES RELACIONADAS CON CNS. (METHODS AND COMPOSITIONS FOR TREATMENT OF CNS DISORDERS.)

Supplementary Protection Certificates for donepezil hydrochloride; memantine hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0296560	SPC/GB97/023	United Kingdom		PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
0296560	2/1998	Austria		PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214

Investment Scenario, Market Dynamics, and Financial Trajectory for Donepezil Hydrochloride and Memantine Hydrochloride

Last updated: February 3, 2026

Executive Summary

This report details the investment horizon, market variables, and financial prospects surrounding two predominant pharmaceuticals used in Alzheimer's disease management: donepezil hydrochloride and memantine hydrochloride. Both drugs exhibit substantial market share growth amid escalating dementia prevalence, with compounded revenues projected over the next decade. Key drivers include demographic shifts, regulatory pathways, patent landscapes, and competitive dynamics.

---

1. Market Overview & Investment Potential

Parameter	Donepezil Hydrochloride	Memantine Hydrochloride
Indications	Mild to moderate Alzheimer's	Moderate to severe Alzheimer's
Global Market Size (2023)	~$1.2 billion	~$780 million
CAGR (2023-2030)	5.2%	4.8%
Projected Revenue (2030)	~$2.2 billion	~$1.4 billion
Patents & Exclusivity	Expired or nearing expiry	Patent expired in some regions
Key Competitors	Novartis, Teva, Sun Pharma	Allergan, Licensees

Summary: Both drugs demonstrate stable, growing markets with high unmet needs. The growth rate, driven by aging demographics, makes them substantial candidates for sustained investment returns, provided patent protections are leveraged or alternative formulations are developed.

---

2. Market Dynamics

2.1 Epidemiological Drivers

Factor	Details	Implication
Aging Population	12% of world population >60 years (UN, 2020); expected to reach 22% by 2050	Increased prevalence of Alzheimer’s disease
Prevalence	~55 million globally (2023); projected to double by 2050	Amplifies demand for symptomatic treatments
Diagnosis Rates	~60-70% of cases diagnosed (Global Deterioration Scale updates)	Underdiagnosis limits market potential

2.2 Regulatory and Patent Landscape

Aspect	Details	Impact on Investment
Patent Status	Donepezil (US patent expired 2017), Memantine (expires 2025 in US)	Patent expiry opens generic markets, compressing margins
Regulatory Approvals	Existing approvals in >50 countries; generics widespread	Entry barriers lowered for new entrants
Off-label & New Applications	Investigation into combination therapies, extended indications	Potential new markets and revenue streams

2.3 Competitive & Pricing Dynamics

Factor	Details	Market Effect
Generics Availability	High after patent expiry; intense price competition	Marginal profit improvements from brand dominance
Pricing Trends	Prices declined post-patent expiry, but branded drugs retain premium	Premium pricing still achievable in emerging markets
Reimbursement Policies	Vary globally; some countries restrict reimbursement for generics	Influences market penetration and revenue streams

---

3. Financial Trajectory

3.1 Revenue Projections (2023-2030)

Donepezil Hydrochloride

Year	Estimated Revenue (USD)	Growth Rate	Notes
2023	$1.2 billion	N/A	Mature, widespread use
2025	$1.4 billion	16.7%	Entry of generics compress profits
2027	$1.75 billion	25.0%	Market expansion, new formulations
2030	$2.2 billion	25.7%	Market stabilization; combo therapies

Memantine Hydrochloride

Year	Estimated Revenue (USD)	Growth Rate	Notes
2023	$780 million	N/A	Moderate penetration, less mature
2025	$950 million	21.8%	Early generic competition intensifies
2027	$1.2 billion	26.3%	Expansion into severe Alzheimer’s care
2030	$1.4 billion	16.7%	Acceptance of combination therapies

Note: CAGR estimates assume continuous demand growth amid patent expirations and generic entry.

3.2 Cost & Quality of Supply Considerations

Parameter	Details	Impact
Manufacturing Cost	Lower post-generic entry; supply chains established	Margin compression, potential for volume-based profits
Supply Chain Risks	Political, logistical, and regulatory disruptions	Potential revenue impact; strategies include diversified sourcing

---

4. Strategic Investment Insights

4.1 Opportunities

• Patent Cliff Management: Positioning for generic competition through product differentiation, new formulations, or combination therapies.
• Emerging Markets: Rapid population aging in Asia-Pacific, Latin America, and Africa suggests high growth potential.
• Research & Development: Investing in novel delivery systems or multi-targeted drugs can add to patent life and margins.
• Acquisition & Alliance: Strategic partnerships with biotech firms developing disease-modifying agents.

4.2 Risks

Risk Factor	Details	Mitigation Strategy
Patent Expiration	Loss of exclusivity in key markets	Develop new formulations or reposition existing drugs
Competitive Pressure	Entry of newer, disease-modifying therapies	Diversify portfolio into early-stage pipeline investments
Regulatory Changes	Stringent approval or reimbursement policies	Engage with policymakers, adopt value-based models
Market Saturation	Decline in branded drug sales post-generic entry	Focus on niche markets and combination therapies

---

5. Comparative Analysis with Alternatives

Parameter	Donepezil Hydrochloride	Memantine Hydrochloride	Other AD Treatments
Patents & Exclusivity	Expired/non-existent	Near expiry	Varies; some experimental drugs
Side Effect Profile	Cholinergic side effects	Neuropsychiatric issues	Varies; some newer agents
Cost per Treatment (USD/year)	$300 - $500	$350 - $580	Higher for new agents
Clinical Effectiveness	Mild to moderate benefit	Moderate benefit	Emerging disease-modifying options

---

6. FAQs

Q1: What are the main drivers behind the growth of donepezil and memantine markets?
A: Aging demographics, increasing prevalence of Alzheimer’s disease, and expanding diagnosis rates primarily drive market growth. Regulatory approvals and off-label uses further augment demand.

Q2: How will patent expirations influence profitability?
A: Patent expirations lead to generic competition, significantly reducing prices and margins for original brands. Companies are investing in new formulations, combination treatments, and pipeline diversification to mitigate these effects.

Q3: Are there new therapies threatening the market share of donepezil and memantine?
A: Yes. Disease-modifying therapies like Aducanumab and Lecanemab, approved in recent years, target underlying pathology but currently serve specific populations. Their long-term impact is uncertain but represents a competitive dynamic.

Q4: Which geographic markets show the highest growth potential?
A: Emerging markets such as China, India, Brazil, and regions in Southeast Asia exhibit rapid growth due to demographic shifts, increasing healthcare access, and evolving regulatory landscapes.

Q5: What strategic approaches can investors pursue in this segment?
A: Investment strategies include supporting companies with diversified portfolios, R&D pipelines, focus on emerging markets, and those actively developing combination or next-generation therapies.

---

7. Key Takeaways

• Market Stability with Growth Potential: Donepezil and memantine continue to demonstrate stable demand with projected revenues reaching over \$3.6 billion by 2030, driven by demographic trends.
• Patent Expiries Create Both Challenges and Opportunities: Generics will impact margins; however, new formulations and combination therapies provide avenues for continued profitability.
• Emerging Markets Are Critical: High growth in populations with rising dementia prevalence makes them attractive for targeted investment strategies.
• Pipeline & Innovation Drive Future Value: Companies investing in disease-modifying agents and novel delivery systems will likely sustain competitive advantages.
• Regulatory Environment Is Dynamic: Ongoing changes necessitate vigilant monitoring of approval processes, reimbursement policies, and patent laws.

---

References

1. United Nations, Department of Economic and Social Affairs, Population Division. (2020). World Population Ageing 2020 Highlights.
2. GlobalData. Alzheimer’s Disease Treatment Market Analysis, 2023-2030.
3. U.S. Food and Drug Administration (FDA). Drug Approvals and Patent Listings, 2023.
4. IQVIA. Global Pharma Market Reports, 2023.
5. World Health Organization. Dementia Fact Sheet, 2022.

---

This comprehensive assessment equips investors, strategists, and stakeholders with actionable insights into the pharmacoeconomic landscape of donepezil hydrochloride and memantine hydrochloride, integrating market size, growth drives, competitive challenges, and future trajectories.